Navigation Links
Maxygen Announces Hold on MAXY-alpha Development Program
Date:9/21/2007

milestone payments and royalties based on any product sales.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. For more information about Maxygen's products and technologies, visit http://www.maxygen.com.

Forward-Looking Statements

This news release contains forward-looking statements about our research and business prospects, including those relating to our ability to develop any human therapeutic products suitable for commercialization; whether Roche will resume the clinical development of our MAXY-alpha product candidates or undertake any other development activities related to the MAXY-alpha development program, and the timing of any such development or activities; the nature, scope and timing of any further evaluation by Roche of the data that resulted in a voluntary hold on the clinical development of MAXY-alpha and whether any such evaluation will adequately assess the meaning or significance of such data or the suitability of MAXY-alpha for further development; the success or continuation of our MAXY-alpha development program and our existing collaboration with Roche; and, if such development program is continued, whether we will receive any future milestone payments or royalties from Roche relating to our MAXY-alpha product candidates. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Among other things these risks and uncertainties include, but are not limited to, changing research and business priorities of Maxygen and/or Roche, the inherent uncertainties of pharmaceutical research and drug development, our ability to develop human therapeutic drugs in an increasingly competitive biotechnology industry and the uncer
'/>"/>

SOURCE Maxygen, Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of JRC-LAMP-vax, ... Japanese red cedar pollen. Phase IC studies began this ... real solution to hay fever. , The Japanese red ... 35 million people in Japan. Mountain Cedar pollen wreaks ...
(Date:8/21/2014)... August 21, 2014 2014 ... Industryā€¯ is a professional and in-depth research ... report provides basic Seaweed Fertilizer information, including ... chain structure as well as industry overview. ... including domestic market as well as global ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere Biosciences, ... their Nutraceutical "TELO-20 for Dogs" with Telomerase ... supplement in the world for dogs. Telomeres are ... chromosome in the body. A wealth of ground-breaking ... in Telomere Science and Aging, including Nobel laureates, ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 Mathematic studies ... Harvard University , and funded by the Jeffrey ... cells within tumors can be visually identified for elimination. These ... growth. The study, which shows a topological map of what ... time in cancer research, for while tumor cells can be ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2
... Management and Patient,Safety Institute (RM&PSI) today announced its ... RM&PSI ( http://www.rmpsi.com ), a subsidiary of FinCor,Holdings ... in,clinical risk management and patient safety programs and ... The spring 2009 calendar also ...
... new white papers detailing sterility testing essentials are ... www.microtestlabs.com ). The white papers, one which ... which is specialized for pharmaceutical manufacturers, presents the ... and reviews different testing methodologies.For medical device manufacturers, ...
... NEOG ) has received approval from the ... its quick and easy BetaStar(R)US test,for dairy antibiotics in ... United States to use Neogen,s new test to comply ... for dairy antibiotics. , Neogen,s ...
Cached Biology Technology:The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates 2The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates 3Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers 2Neogen's BetaStar(R) US Dairy Antibiotic Test Approved by FDA/NCIMS 2
(Date:8/21/2014)... study of American singles found that during sex ... orgasm rates. On average, men experience orgasm 85.1 ... making little difference. For women, however, orgasm occurrence ... 62.9 percent of the time during sex with ... with women,s sexual orientation, with lesbian women experiencing ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- LiveScan Service ... agreed to a partnership with Gabriel Health Institute, ... fastest growing Certified Nursing Assistant preparatory schools. ...  an exclusive member of Binary,s LiveScan service provider,s ... will improve its service capabilities by widening ...
(Date:8/21/2014)... window? It consists of radiations in the 3.3 to ... water in biological tissues. New theoretical findings show that ... water window. These could be the basis of an ... biological samples or to be used in high-precision spectroscopy. ... needed to efficiently generate the harmonic radiationswhich are multiples ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3Water window imaging opportunity 2
... to each person or set of identical twins. That ... crime detection to international travel. But what happens when ... patterns of ridges? It,s not the premise ... known as adermatoglyphia. It,s also known as "Immigration Delay ...
... on the detrimental impact of some common medicines on elderly people ... a few of these medicines does not appear to cause further ... In a paper published today by the journal ... East Anglia (UEA) and colleagues from a number of other universities ...
... - The first fluorescence-guided surgery on an ovarian cancer patient ... agent created by a Purdue University researcher. The surgery ... phase of a clinical trial to evaluate a new technology ... ovarian cancer patients. The method illuminates cancer cells to help ...
Cached Biology News:Shake hands with the invisible man 2Reassurance for dementia sufferers on impact of common drugs 2Purdue technology used in first fluorescence-guided ovarian cancer surgery 2Purdue technology used in first fluorescence-guided ovarian cancer surgery 3Purdue technology used in first fluorescence-guided ovarian cancer surgery 4
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
... Zeba Desalt Spin Columns contain a proprietary ... offers exceptional desalting and protein-recovery characteristics compared ... as low as 25 g/ml of protein ... and > 95% retention of salts and ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Biology Products: